MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) - Clinical Trial NCTNCT06128629

Business Opportunities for NCT06128629

Connect with principal investigators, study coordinators, and key decision makers for this PHASE3 trial studying investigational therapy for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.

Clinical Trial Information

Study Sponsor

Sponsor information available

Drug/Intervention

Study intervention details available

Therapeutic Area

Amyloid Neuropathies, Familial, Cardiomyopathies, Amyloidosis

Study Phase

PHASE3

Study Status

RECRUITING

NCT Number

NCTNCT06128629

Find Contact Information

Access exclusive contact details for:

• Principal investigators and sub-investigators
• Study coordinators and research staff
• Site directors and facility contacts
• Sponsor representatives and CRO partners
• Business development professionals
• Clinical operations managers

Clinical Trial Locations

This study has 127 locations across United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom.

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships